S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
All the trading advice you’ve ever received boils down to this (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Aquestive Therapeutics Stock Price, News & Analysis (NASDAQ:AQST)

$2.47
+0.08 (+3.35%)
(As of 12/4/2023 ET)
Compare
Today's Range
$2.35
$2.67
50-Day Range
$1.30
$2.47
52-Week Range
$0.72
$2.69
Volume
1.07 million shs
Average Volume
381,794 shs
Market Capitalization
$164.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Aquestive Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.9% Upside
$6.00 Price Target
Short Interest
Healthy
2.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.88mentions of Aquestive Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.07) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

679th out of 952 stocks

Pharmaceutical Preparations Industry

318th out of 434 stocks


AQST stock logo

About Aquestive Therapeutics Stock (NASDAQ:AQST)

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

AQST Stock Price History

AQST Stock News Headlines

Best Momentum Stocks to Buy for November 28th
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Aquestive Therapeutics Inc AQST
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Preview: Aquestive Therapeutics's Earnings
Wedbush Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)
See More Headlines
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+142.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-54,410,000.00
Pretax Margin
-24.90%

Debt

Sales & Book Value

Annual Sales
$47.68 million
Book Value
($2.19) per share

Miscellaneous

Free Float
61,165,000
Market Cap
$164.92 million
Optionable
Not Optionable
Beta
2.73
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Daniel Barber (Age 47)
    CEO, President & Director
    Comp: $925.35k
  • Mr. Alexander Mark Schobel (Age 64)
    Chief Innovation & Technology Officer
    Comp: $672.69k
  • Ms. Lori J. Braender BSBA (Age 67)
    Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $678.76k
  • Mr. A. Ernest Toth Jr. (Age 64)
    Chief Financial Officer
    Comp: $679.9k
  • Ms. Cassie Jung (Age 44)
    Senior Vice President of Operations
  • Mr. Peter E. Boyd (Age 57)
    Senior Vice President of IT, HR & Communications
  • Mr. Kenneth W. Marshall (Age 64)
    Chief Commercial Officer
  • Dr. Gary H. Slatko M.D. (Age 66)
    MBA, Chief Medical Officer
  • Dr. Stephen Wargacki (Age 45)
    Senior VP of Research & Development
  • Dr. Carl N. Kraus M.D. (Age 53)
    Chief Medical Officer














AQST Stock Analysis - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 1 year price objectives for Aquestive Therapeutics' stock. Their AQST share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2023?

Aquestive Therapeutics' stock was trading at $0.9021 at the beginning of 2023. Since then, AQST stock has increased by 173.8% and is now trading at $2.47.
View the best growth stocks for 2023 here
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our AQST earnings forecast
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings results on Monday, November, 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $11.33 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Organigram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

Who are Aquestive Therapeutics' major shareholders?

Aquestive Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.19%), Acadian Asset Management LLC (0.82%), Connor Clark & Lunn Investment Management Ltd. (0.37%), Walleye Capital LLC (0.23%), GSA Capital Partners LLP (0.15%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Alexander Mark Schobel, Daniel Barber, Lori J Braender and Peter E Boyd.
View institutional ownership trends
.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AQST) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -